Omicia, Inc.

Emeryville, CA 94608

SBIR Award Summary

Total Number of Awards 17
Total Value of Awards $5.4MM
First Award Date 08/01/03
Most Recent Award Date 09/01/13

Key Personnel

Last Name Name Awards Contact
Reese Martin G Reese 16 Message
Bader Joel S. Bader 2
Eilbeck Karen Louise Eilbeck 1
Yandell Mark Douglas Yandell 5

17 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: RFA-HG-10-019
Budget: 09/01/13 - 08/31/14

DESCRIPTION (provided by applicant): Taking sequence to bedside is the stated and primary focus of the NHGRI for the next 5 years. Ironically, cheap genome sequencing is now producing analysis bottlenecks, especially as regards the clinical interpretation of genetic variants. The purpose of this SBIR FastTrack proposal is to obtain funding for t...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: RFA-HG-10-019
Budget: 09/10/12 - 08/31/13

DESCRIPTION (provided by applicant): Taking sequence to bedside is the stated and primary focus of the NHGRI for the next 5 years. Ironically, cheap genome sequencing is now producing analysis bottlenecks, especially as regards the clinical interpretation of genetic variants. The purpose of this SBIR FastTrack proposal is to obtain funding for t...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: RFA-HG-10-019
Budget: 06/06/12 - 08/31/12

DESCRIPTION (provided by applicant): Taking sequence to bedside is the stated and primary focus of the NHGRI for the next 5 years. Ironically, cheap genome sequencing is now producing analysis bottlenecks, especially as regards the clinical interpretation of genetic variants. The purpose of this SBIR FastTrack proposal is to obtain funding for t...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PAR-09-220
Budget: 09/30/10 - 03/30/12

DESCRIPTION (provided by applicant): High-throughput sequencing technologies are beginning to deliver complete individual genome sequences. However, significant barriers still obstruct the use of these data for basic research and in clinical evaluation for personalized medicine. One major barrier is the absence of tools for variant annotation wi...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-120
Budget: 09/10/10 - 08/31/12

DESCRIPTION (provided by applicant): The convergence of recent advances in genome sequencing, genotyping and identification of disease markers has led to the development of the nascent field of personalized medicine, in which an individual's biomarkers can be used to predict his or her disease risks and responsiveness to treatments. Omicia is in...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-080
Budget: 09/07/10 - 02/28/12

DESCRIPTION (provided by applicant): Genetic Hotspots: The goal of this Phase 1 SBIR project is to develop and apply new methods to identify genes that harbor genetic variants that affect disease risk. The long-term objective of this work is to identify genes and gene variants that can improve human health by providing greater information abo...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-050
Budget: 07/01/10 - 06/30/12

DESCRIPTION (provided by applicant): High-throughput genotyping, expression, and sequencing technologies and the development of increasingly sophisticated methods for predicting gene-disease interactions have given the new field of genomic-based personalized medicine a wealth of data: more, in fact, than can easily be processed and interpreted. ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-050
Budget: 08/28/09 - 06/30/10

DESCRIPTION (provided by applicant): High-throughput genotyping, expression, and sequencing technologies and the development of increasingly sophisticated methods for predicting gene-disease interactions have given the new field of genomic-based personalized medicine a wealth of data: more, in fact, than can easily be processed and interpreted. ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-120
Budget: 08/01/09 - 08/31/12

DESCRIPTION (provided by applicant): The convergence of recent advances in genome sequencing, genotyping and identification of disease markers has led to the development of the nascent field of personalized medicine, in which an individual's biomarkers can be used to predict his or her disease risks and responsiveness to treatments. Omicia is in...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-20
Budget: 09/26/08 - 07/31/09

DESCRIPTION (provided by applicant): The convergence of recent advances in genome sequencing, genotyping and identification of disease markers has led to the development of the nascent field of personalized medicine, in which an individual's biomarkers can be used to predict his or her disease risks and responsiveness to treatments. Omicia is in...

Load More